LQDA logo

LQDA
Liquidia Corp

4,249
Mkt Cap
$3.33B
Volume
1.35M
52W High
$46.67
52W Low
$11.26
PE Ratio
-45.05
LQDA Fundamentals
Price
$37.47
Prev Close
$37.74
Open
$38.29
50D MA
$37.54
Beta
0.87
Avg. Volume
1.36M
EPS (Annual)
-$0.8009
P/B
73.02
Rev/Employee
$732,962.96
$2,975.43
Loading...
Loading...
News
all
press releases
Notable Wednesday Option Activity: LQDA, CRK, TH
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Liquidia Corp (Symbol: LQDA), where a total of 11,898 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 88.2...
Nasdaq News: Markets·5h ago
News Placeholder
More News
News Placeholder
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Zacks·10h ago
News Placeholder
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Zacks·1d ago
News Placeholder
Tudor Investment Corp ET AL Makes New $1.54 Million Investment in Liquidia Corporation $LQDA
Tudor Investment Corp ET AL bought a new position in shares of Liquidia Corporation (NASDAQ:LQDA - Free Report) during the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·3d ago
News Placeholder
The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M
Key PointsScott Moomaw sold 80,000 shares of common stock for a transaction value of approximately ~$2.83 million on March 9, 2026...
Nasdaq News: Markets·4d ago
News Placeholder
Novartis Bolsters Immunology Pipeline With Excellergy Deal
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
Zacks·5d ago
News Placeholder
Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 18,314 Shares
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Scott Moomaw sold 18,314 shares of the business's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an...
MarketBeat·7d ago
News Placeholder
Scott Moomaw Sells 18,314 Shares of Liquidia (NASDAQ:LQDA) Stock
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Scott Moomaw sold 18,314 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price...
MarketBeat·7d ago
News Placeholder
Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares
Key PointsThe chief medical officer of Liquidia sold 35,365 common shares on March 13, 2026, for a transaction value of $1.28 million at around $36.30 per share...
Nasdaq News: Markets·8d ago
News Placeholder
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.
Zacks·9d ago
<
1
2
...
>

Latest LQDA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.